Hengrui Medicine Announces Subsidiary's Approval for SHR-A2009 Injection Clinical Trial

2025-09-02 / Read about 0 minute

Author：小编

Hengrui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has recently secured the Drug Clinical Trial Approval Notice from the National Medical Products Administration for SHR-A2009 Injection. This groundbreaking antibody-drug conjugate (ADC) specifically targets HER3, a field where no comparable treatments currently exist on the global market. Upon receiving this approval, Suzhou Shengdiya Biopharmaceutical Co., Ltd. will promptly commence clinical trials for SHR-A2009, aiming to assess its safety, tolerability, and efficacy in patients suffering from advanced solid tumors.

Previous page：SFC Imposes Lifetime Industry Ban on Former UBS Vi...

Next page：US Companies Face Unprecedented CEO Turnover, Mark...

Return to List

Hot Reading

16 hour ago

Report: Samsung execs worried company could lose money on smartphones for the first time

2 day ago

BMW’s flagship 7 Series gets its ‘Neue Klasse’ upgrade

2 day ago

Tesla’s revenue rises again as it prepares for more AI and robotics

2 day ago

Google unveils two new TPUs designed for the "agentic era"